Janssen Biotech has announced the FDA approval of Simponi (golimumab) to treat moderately to severely active ulcerative colitis (UC) in adult patients with corticosteroid dependence or an inadequate response to or failed to tolerate oral ...
Tags: FDA, Janssen Biotech
Specialty biopharmaceutical company Santarus has announced the commercial launch of ulcerative colitis therapy, Uceris (budesonide) extended release tablets. Uceris that contains a locally acting glucocorticosteroid, budesonide, in a ...
Tags: Santarus, Uceris, ulcerative colitis therapy
The US FDA has approved Warner Chilcott's 400mg mesalamine product as new ulcerative colitis therapy, to be marketed as Delzicol. Warner expects to commercially launch Delzicol in March 2013. Delzicol delayed-release capsules are ...
Santarus has obtained FDA approval for ulcerative colitis therapy, Uceris (budesonide) extended release tablets. A 9mg dose tablet is approved for administration once a day in adult patients with ulcerative colitis for up to eight weeks. ...
Biotechnology company Avaxia Biologics has received AVX-470 investigational new drug (IND) application clearance for the treatment of ulcerative colitis from the FDA. The bovine anti-tumor necrosis factor polyclonal antibody is based on ...
Tags: Avaxia, Ulcerative Colitis Therapy, IND
The USFDA has approved Abbott's Humira (adalimumab) for the treatment of adult patients with moderate to severe Ulcerative Colitis (UC) when certain other medicines have not worked well enough. Humira, which works by inhibiting tumour ...
Tags: FDA, Abbott Humira, Ulcerative Colitis